Comparison between vestibular and subcutaneous insertion of deslorelin implants for oestrus induction in bitches.
Investigations using sustained-release deslorelin implants at various insertion sites have shown that this method consistently induces oestrus in anoestus bitches. However, fertility comparisons between implant insertion sites have not been performed. Anestrous beagle bitches received one 2.1 mg deslorelin implant beneath the vestibular mucosa (VM group; n = 6) or in the subcutaneous tissue between the shoulder blades (SubQ group; n = 8). Vestibular implants were removed when serum progesterone concentrations first exceeded 1.5 ng/ml. Vaginal cytologies and blood samples were collected daily and bitches were inseminated during oestrus. Serum progesterone and deslorelin concentrations were measured and pregnancy status was determined using ultrasonography. There were no differences between groups in the intervals between implant administration and the onset of proestrus, the time of the luteinizing hormone surge and the onset of cytologic diestrus. There were also no differences in the number of corpora lutea or foetuses. However, conception rate was significantly lower in the SubQ group. The pregnancy rate did not differ significantly between the VM and SubQ groups [4 out of 6 (66.7%) and 3 out of 8 (37.5%), respectively]. One bitch (16.7%) in the VM group and three bitches (37.5%) in the SubQ group suffered distinct, premature declines in serum progesterone concentrations starting 1-4 weeks after cytologic diestrus. Serum progesterone concentrations did not recover (premature luteal failure), resulting in abortion. Bitches with premature luteal failure in the SubQ group still had serum deslorelin concentrations >100 pg/ml 20 days after implant insertion, suggesting a possible association between prolonged deslorelin release and luteal failure.
Kutzler
M
M
Department of Clinical Sciences, Oregon State University, Corvallis, OR 97331, USA. michelle.kutzler@oregonstate.edu
Lamb
S V
SV
Volkmann
D
D
D000818:Animals; D004285:Dogs; D004343:Drug Implants; D030762:Estrous Cycle / Q000187:drug effects*; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction / Q000662:veterinary*; D011247:Pregnancy; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D014844:Vulva
D004343:Drug Implants; D017329:Triptorelin Pamoate; D007986:Luteinizing Hormone; C066438:deslorelin